Microbot Medical (MBOT) Q2 2026 earnings summary

Executive summary

• Achieved first commercial revenues from the LIBERTY® Endovascular Robotic System, transitioning from limited to full market release in April 2026, with $346,000 in revenue recognized for the six months ended June 30, 2026.

• Revenue and customer base more than doubled sequentially from Q1 to Q2 2026, driven by repeat orders, expanded utilization, and new customer acquisitions following the Full Market Release.

• Expanded into new states and increased the number of hospital sites using the LIBERTY System, with broader adoption across multiple procedure types.

• Broadened sales footprint from four to eight territories, targeting 12 by year-end.

• Continued focus on commercialization, R&D for new applications, and expansion of sales and marketing teams.

Financial highlights

• Revenue for the six months ended June 30, 2026: $346,000, compared to $0 in the prior year period.

• Net loss for the six months ended June 30, 2026: $9.3 million, compared to $6.1 million in the prior year period.

• Gross loss for the six months ended June 30, 2026: $641,000.

• Cash and marketable securities totaled $67.4 million as of June 30, 2026.

• Total revenue increased by over 100% compared to the first quarter of 2026.

Outlook and guidance

• Expects continued net losses as commercialization and R&D efforts expand.

• Management believes available funds are sufficient to fund operations for more than twelve months from the reporting date.

• Plans to pursue additional capital through equity/debt offerings and government grants.

• Plans to expand production capacity with a second manufacturing site to support anticipated U.S. and international demand.

• Preparing for commercial readiness in Europe, anticipating CE Mark approval.